Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Lille – page 73

1 340 clinical trials in Lille, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Lille at a glance
1 340
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

1 340 trials in Lille

Open in trial search

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

B-cell lymphoma recurrent+1

Not recruiting

Study on the Safety and Effectiveness of Glofitamab and Obinutuzumab for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:F. Hoffmann-La Roche AG

Ischaemic stroke+1

Not recruiting

Study of cangrelor with mechanical thrombectomy in patients with acute ischemic stroke selected by perfusion imaging

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cangrelor Tetrasodium
  • Sponsor:Fondation A De Rothschild

Migraine

Not recruiting

Study on Rimegepant for Treating Migraine in Adults Who Cannot Use Triptans

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rimegepant
  • Sponsor:Pfizer Inc.

Paresis

Not recruiting

Study on the Effectiveness and Safety of NT 201 (Botulinum Toxin) for Treating Lower Limb Spasticity in Adults After Stroke or Traumatic Brain Injury

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
  • Sponsor:Merz Pharmaceuticals GmbH

Neuroblastoma

Not recruiting

Study on the Safety of Lutetium (177Lu) Oxodotreotide with Arginine and Lysine in Children with Refractory or Recurrent Neuroblastoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Lysine Hydrochloride
  • Sponsor:Oncopole Claudius Regaud

Frontotemporal dementia

Not recruiting

Study on the Safety and Effects of LY3884963 for Patients with Fronto-Temporal Dementia with Progranulin Mutations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Methylprednisolone
  • Sponsor:Prevail Therapeutics Inc.

Glioma

Not recruiting

Study of Abemaciclib and Temozolomide for Children and Young Adults with Newly Diagnosed High-Grade Glioma After Radiotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Glycogen storage disease type II

Not recruiting

Long-Term Safety Study of Avalglucosidase Alfa for Patients with Pompe Disease in France

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Avalglucosidase Alfa
  • Sponsor:Sanofi Winthrop Industrie

Pemphigoid

Not recruiting

Study of dupilumab effectiveness compared to placebo in adults with bullous pemphigoid

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Prostate cancer

Not recruiting

Study on Darolutamide with Radiation Therapy for Patients with Intermediate Unfavorable Risk Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Institut Bergonie

Peripheral T-cell lymphoma unspecified

Not recruiting

Study of Lacutamab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:LYSARC

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Lille

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on head and neck squamous cell carcinoma, exploring novel treatment combinations and targeted therapies. Additional research includes investigations into pancreatic cancer and gastric cancer treatments.

  • Advanced cancer therapies
  • Targeted molecular treatments
  • Combination therapy approaches

Studies are evaluating innovative therapeutic agents and their effectiveness in treating various forms of cancer.

02 Neurological Disorders

Comprehensive research into Alzheimer's disease and Amyotrophic Lateral Sclerosis, examining new treatment approaches and disease mechanisms. Studies also include investigations of essential tremor treatments.

  • Neurodegenerative diseases
  • Movement disorders
  • Brain imaging studies

Research focuses on understanding disease progression and developing targeted interventions.

03 Autoimmune and Inflammatory Conditions

Innovative trials examining treatments for Crohn's disease and Multiple Sclerosis. Research includes novel approaches to managing chronic inflammatory conditions and immune system disorders.

  • Inflammatory bowel diseases
  • Immunotherapy approaches
  • Disease modification strategies

Studies aim to improve treatment outcomes and develop more effective therapeutic options.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.